A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

NCT07713459 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma Nonhodgkin
Marginal Zone B Cell Lymphoma
Diffuse Large B Cell Lymphoma (DLBCL)
Follicular B-cell Non-Hodgkin's Lymphoma
CAR T Cell Therapy

Interventions

BIOLOGICAL: CART Infusion

Sponsor

Kure Cells, INC